Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Follow-on Biologics Savings Lower In Administration’s Budget Proposal

This article was originally published in The Pink Sheet Daily

Executive Summary

FOB pathway would create only $6.35 billion in savings, according to the budget, down from the $9.24 billion projected in February.
Advertisement

Related Content

Follow-On Biologics Legislation Could Come Down to Horse-Trading
Follow-On Biologics Legislation Could Come Down to Horse-Trading
Public Policy – Not The Economy – Must Be Biotech Sector’s Focus, BIO CEO Says
Public Policy – Not The Economy – Must Be Biotech Sector’s Focus, BIO CEO Says
Follow-On Biologics Legislation Faces Tough Road Ahead; Momentum Stalled
Follow The Follow-On Money: Obama’s Budget Has Modest Biogeneric Savings
Follow The Follow-On Money: Obama’s Budget Has Modest Biogeneric Savings
Follow-On Biologics Coding Tweaks Could Raise Savings By 30% – CBO
Biogenerics Get A Low Score From CBO, But Is BIO Actually The Loser?

Topics

Advertisement
UsernamePublicRestriction

Register

PS069433

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel